Snovitra (vardenafil hydrochloride) is a potent phosphodiesterase type 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). As a prescription medication, it functions by enhancing blood flow to specific areas of the body, facilitating improved erectile function in men and reducing pulmonary vascular resistance in PAH patients. Its rapid onset and sustained duration of action make it a preferred choice among healthcare providers seeking reliable therapeutic outcomes. Clinical evidence supports its efficacy and safety profile when used under appropriate medical supervision.

Features

• Active ingredient: Vardenafil hydrochloride
• Available dosages: 5mg, 10mg, 20mg film-coated tablets
• Rapid onset of action: as early as 25 minutes post-administration
• Extended duration: efficacy up to 8–10 hours
• High selectivity for PDE5 enzyme inhibition
• Orally disintegrating tablet formulation available for convenience
• Manufactured under strict Good Manufacturing Practice (GMP) guidelines

Benefits

• Significantly improves the ability to achieve and maintain an erection sufficient for satisfactory sexual activity.
• Enhances overall sexual confidence and relationship satisfaction.
• Provides predictable and reliable pharmacokinetics for planned intimacy.
• Reduces symptom burden in pulmonary arterial hypertension, improving exercise capacity.
• Offers flexibility in dosing to accommodate individual patient response and tolerability.
• Supported by extensive clinical research demonstrating both efficacy and patient acceptability.

Common use

Snovitra is primarily prescribed for the management of erectile dysfunction in adult males. It is also used off-label in certain cases of pulmonary arterial hypertension, though this application should be strictly guided by a specialist. The medication is intended for use prior to anticipated sexual activity and is not meant for continuous daily dosing unless specifically advised for PAH management. It requires sexual stimulation to be effective and does not automatically induce an erection.

Dosage and direction

For erectile dysfunction, the recommended starting dose is 10mg taken orally approximately 25–60 minutes before sexual activity. Based on efficacy and tolerability, the dose may be increased to 20mg or decreased to 5mg. The maximum recommended dosing frequency is once per day. For pulmonary arterial hypertension, dosing must be individualized under specialist supervision, often starting at 5mg twice daily. Tablets should be swallowed whole with a glass of water; the orodispersible formulation should be placed on the tongue and allowed to dissolve without water. Avoid high-fat meals around the time of administration, as they can delay absorption.

Precautions

Patients with cardiovascular disease, including unstable angina, recent myocardial infarction, or uncontrolled hypertension, should use Snovitra with extreme caution. Those with anatomical deformation of the penis (such as Peyronie’s disease) or conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma) require careful evaluation before use. Caution is advised in patients with severe hepatic impairment (Child-Pugh class C) or severe renal impairment (CrCl < 30 mL/min). Vision changes, including non-arteritic anterior ischemic optic neuropathy (NAION), have been reported rarely with PDE5 inhibitors. Patients should avoid excessive alcohol consumption while using this medication.

Contraindications

Snovitra is contraindicated in patients taking any form of organic nitrates or nitric oxide donors, such as nitroglycerin, isosorbide mononitrate, or amyl nitrite, due to the risk of profound hypotension. It is also contraindicated in individuals with a known hypersensitivity to vardenafil or any excipients in the formulation. Use is prohibited in patients with severe hepatic impairment, hypotension (BP < 90/50 mmHg), recent stroke or life-threatening arrhythmia, and hereditary degenerative retinal disorders.

Possible side effects

Common adverse reactions (≥2%) include headache, flushing, dyspepsia, nasal congestion, dizziness, and back pain. Less frequently, patients may experience visual disturbances (blurred vision, cyanopsia), palpitations, sinusitis, or myalgia. Serious but rare side effects include priapism, sudden hearing loss, severe hypotension, and cardiovascular events. Allergic reactions, though uncommon, may present as rash, urticaria, or swelling of the face and lips. Most side effects are mild to moderate and transient in nature.

Drug interaction

Snovitra is primarily metabolized by CYP3A4 enzymes. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) is not recommended; if unavoidable, the dose should not exceed 5mg in 24 hours. Alpha-blockers (e.g., doxazosin, tamsulosin) may potentiate hypotensive effects—concurrent use should be approached with caution. Other antihypertensives may have additive blood pressure-lowering effects. Avoid use with other PDE5 inhibitors. Grapefruit juice may increase vardenafil plasma concentrations and should be avoided.

Missed dose

As Snovitra is taken on an as-needed basis for erectile dysfunction, the concept of a “missed dose” does not apply. For patients using it under supervision for pulmonary arterial hypertension on a scheduled regimen, if a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose is not recommended.

Overdose

In cases of overdose, standard supportive measures should be employed. Expected effects would be an extension of the drug’s vasodilatory properties, including severe hypotension, syncope, and prolonged erection. Priapism lasting more than 4 hours requires immediate medical intervention to avoid permanent tissue damage. Hemodialysis is not expected to significantly eliminate vardenafil due to high protein binding and extensive tissue distribution.

Storage

Store at room temperature (15–30°C or 59–86°F) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to alternative containers, as this may expose them to humidity and reduce stability.

Disclaimer

This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new medication or changing an existing treatment plan. Do not disregard or delay seeking medical advice based on content provided here. Individual patient needs and responses may vary.

Reviews

Clinical studies and post-marketing surveillance indicate high patient satisfaction with Snovitra, particularly noting its rapid onset and prolonged window of effectiveness. Many users report improved erectile function and quality of life. In pulmonary arterial hypertension applications, it has been shown to improve exercise tolerance and functional capacity. As with all prescription medications, results can vary, and adherence to prescribed guidelines is essential for optimal outcomes.